New tool reveals DNA structures that influence disease
Researchers have created an algorithm that locates and analyses DNA structures which are linked to the development of certain diseases.
List view / Grid view
Researchers have created an algorithm that locates and analyses DNA structures which are linked to the development of certain diseases.
A survey has shown that the pharmaceutical industry believes R&D will see a lot of benefit from digital transformation and that AI will be at the forefront.
This issue includes a discussion on the future of high-throughput screening through collaboration, an analysis of mass spectrometry as a structural biology tool and an exploration of the challenges of hit-to-lead when researching tropical diseases. Also in the issue are articles on immuno-oncology and assays.
A new discovery could lead to the development of a drug for untreatable strains of TB, which can target uptake of the very amino acid that enables the bacteria to spread within the body.
A study has shown that unintended mutations from gene editing with CRISPR-Cas9 are rare in zebrafish, providing reassurance that this technology is a valid tool with great promise for the treatment of genetic disorders.
The ICR has revealed that during drug discovery, researchers should not use general search engines and vendor catalogue information to decide on their use of chemical probes.
Research has found that artificial intelligence in drug discovery will be worth $1,434 million by the end of 2024.
On 5-6 November, ACC Liverpool hosted the ELRIG Drug Discovery event, which allowed R&D professionals to come together and discuss the latest industry developments.
The CyBio FeliX pipetting system was used to perform all liquid handling steps of the library preparation workflow for personal genome analysis.
A novel computational method has led to the discovery of genes whose alteration may contribute to cancer susceptibility and may lead to new therapeutic targets for cancers.
Researchers in Australia and the US have launched the first open-source database detailing genetic variants that impact human health and disease.
New software has been developed that can reveal the detailed RNA-binding properties of proteins, which is important for characterising the pathology of many diseases.
A machine-learning algorithm has been created that automates high-throughput screens of epigenetic medicines.
A drug discovery platform for mental health treatment could also help to identify mechanisms for the treatment of substance use disorders.
Researchers have developed CRISPR-Cas13 enzyme-based technology that can be programmed to both detect and destroy RNA-based viruses in human cells.